Alere Inc
Most Recent
What You Need to Know about the Abbott Labs Side of the Alere-Abbott Merger
Abbott Laboratories is a leading pharmaceutical company that also makes diagnostic products, nutritional products, and vascular products.
Leveraged Loan Funds: Ongoing Outflows in June
Last week’s quantum of outflows was $223 million. This brings the total net outflows from leveraged loan funds to $4.3 billion year-to-date.
Waters Introduces Symphony, Its New Data Pipeline Software
A top IHI performer on June 2, 2016, was Waters (WAT), which rose 0.9%. The company was in the news with the introduction of its new data pipeline software.
A Brief Recap of the Abbott–Alere Deal Developments
Three months after announcing a $5.8 billion deal in which Abbott Laboratories (ABT) would buy Alere (ALR), Alere rejected Abbott’s $50 million offer to end the deal. On December 7, Abbott sued Alere to terminate the deal.
Abbott-Alere Deal Wins Conditional US Antitrust Approval
The Federal Trade Commission recently announced the US antitrust approval for Abbott Laboratories’ (ABT) acquisition of Alere (ALR).
What Were Abbott’s Key Growth Drivers for 2Q17?
Abbott completed the acquisition of St. Jude Medical in January 2017. It contributed significantly to its 2Q17 sales.
Does Novartis See Much Potential for Its Surgical Business?
In 2017, Novartis (NVS) has planned to conduct a review of its Alcon segment to evaluate the business’s growth potential.
Alere’s Response to Abbott Laboratories’s Lawsuit to Terminate the Merger
Alere (ALR) denied claims that any of the events that occurred during the last ten months would constitute any material change to the company’s value.
Abbott’s Stock Prices Fell despite Strong 3Q16 Results
On October 19, Abbott Laboratories (ABT) released its 3Q16 earnings. After the announcement, its share price fell ~2% from $41.2 on October 18, 2016.
The Rationale behind Johnson & Johnson’s Acquisition of Abbott Medical Optics
On September 16, 2016, Johnson & Johnson announced the acquisition of Abbott Medical Optics, a subsidiary of Abbott Laboratories, and its stock fell ~0.3%.
Rationale for the St. Jude Medical-Abbott Merger Transaction
Abbott Labs is buying St. Jude Medical for about $30 billion in cash, stock, and assumed debt to become a dominant player in the cardiovascular health space.
The Alere-Abbott Labs Merger: Understanding the Alere Side
Alere provides diagnostic solutions in the healthcare industry, primarily in infectious disease. Abbott Labs is buying Alere to boost its diagnostics line.
Cepheid’s Revenue and Income Fell in 3Q15
After its 3Q15 earnings report, Cepheid fell by 0.86% to close at $32.25 per share as of October 20, 2015, with a 4.8% fall in revenue in 3Q15.
Steven Cohen’s Point72 Asset Management’s 3Q14 positions
Point72 Asset Management’s portfolio decreased slightly to $13.2 billion in the third quarter—compared to $15.6 billion in the second quarter. The third quarter ended in September.
